AstraZeneca, a global, innovation-driven, integrated biopharmaceutical company, announced recently that Mark Mallon had been appointed as president of AstraZeneca China. He will be responsible for the company's business operations in China. The appointment will be effective on May, 1.
"China is one of our biggest growth opportunities and core to our emerging markets strategy," said Rudd Dobber, regional vice-president of AstraZeneca Asian-Pacific.
"Mark steps in at an exciting time for the China team after enjoying continual growth over the last several years. I believe that the China marketing company will benefit from Mark's passion for developing people and his engaging leadership style. In addition, his global experience in successfully leading large organizations, launching major products, and introducing new approaches to meet our customer needs will complement our strong local market capabilities."
"I am very excited about the upcoming tasks ahead. AstraZeneca China has achieved huge success in past years, as a result of our long-term commitment to the Chinese market," said Mark Mallon.
"I will lead the Chinese team on a continuous mission to increase our investment in China, so as to bring a meaningful difference to the lives of more Chinese patients through high-quality medicines. We will aim to further penetrate the Chinese market with the ethical principle of integrity, while establishing deeper connections with all our stakeholders and combining our joint forces to achieve common goals."
Previously, Mark Mallon serves as Representative Director, Executive Vice-President and Chief Operating Officer of AstraZeneca KK (Japan), a role he assumed in April 2009 when he was responsible for all of AZKK's marketing, sales and commercial operations.
AstraZeneca China has its headquarters in Shanghai, with presence in major cities across China. It has more than 4,500 employees working in manufacturing, sales, clinical research and new product development.